Neutrophils orchestrate the innate immune response against microorganisms and are increasingly recognized to modulate cancer development in primary tumors and metastases.
Summary:
Neutrophils orchestrate the innate immune response against microorganisms and are increasingly recognized to modulate cancer development in primary tumors and metastases.
To address their function in vivo, different approaches are used, the most common ones relying on antibody-mediated neutrophil depletion. By comparing the effects of two widely used antibodies, we demonstrate a strong efficacy but a lack of specificity for anti-Gr1. In contrast, anti-Ly6G lacks neutrophil-depletion capacity in C57BL/6 mice, which can be explained by an insufficient celerity of neutrophil clearance that is counterbalanced by exacerbated mobilization of immature cells. When combined with a secondary antibody, antiLy6G treatment results in specific and efficient neutrophil depletion. Using a mouse model of lung adenocarcinoma, we demonstrate the efficacy of this new approach to diminish primary tumor growth and propose the existence of a local intercellular communication between neutrophils and alveolar macrophages that fosters regulatory T cell proliferation in lung cancer.
INTRODUCTION
Neutrophils are the most abundant cell type among human leukocytes and play an essential role in host defense against bacteria and in sterile inflammation 1 . They were among the first immune cell types associated with cancer progression 2 and their involvement in autoimmune diseases such as antibody-associated systemic vasculitis, atherosclerosis, systemic lupus erythematous, rheumatoid arthritis, psoriasis [3] [4] [5] and wound repair 6 positions them as an essential component in multiple immunological processes. Furthermore, it has recently been shown that neutrophils infiltrate multiple tissues where they instruct homeostatic and pathological conditions by contributing to circadian gene regulation 7 . They are constantly produced and released in the bloodstream by the bone marrow (BM) 8 and are rapidly cleared within about twelve hours in tissues (spleen, BM and liver) through the action of resident phagocytes 9 . BM neutropoiesis involves about forty percent of BM cells and is tightly regulated through the IL23/IL17/G-CSF axis, itself governed by gut macrophages in physiological conditions 7, 10, 11 .
Whereas neutrophils can be easily purified from blood and BM, their short half-life, absence of proliferation and high sensitivity to environmental conditions leads to important limitations to study them functionally in vitro. Hence, in vivo depletion experiments and genetic engineering allowing conditional gene knockouts and reporters are the most relevant approaches to investigate neutrophil biology in various contexts. In mice, neutrophils are characterized by the expression of both Ly6G and Ly6C antigens, with Ly6G being restricted to neutrophils 12 . Until 2008, depletion-based experiments suffered from a lack of specific antibodies (ab) allowing neutrophil targeting without impacting other immune populations.
Indeed, the anti-Ly6G/C Gr1 ab (clone RB6-8C5) was extensively used to deplete these cells, but due to its ability to bind both Ly6C and Ly6G antigens, this ab also depletes Ly6C + monocytes and a subset of CD8 T cells, potentially reducing the relevance of the observations. The characterization of the anti-Ly6G specific ab (Clone 1A8) has provided new possibilities, as it only binds neutrophils and seems to be the most relevant agent to target specifically these cells in vivo 13 . Genetic approaches based on LysM-Cre 14, 15 or MRP8/S100A8-Cre 16 were developed to manipulate and trace neutrophils in vivo but the transgenes are also expressed at least transiently by other myeloid lineages when bred with ROSA-EYFP (Gt(ROSA)26Sor tm1(EYFP)Cos ) animals 17 . Recently, the knockin of a bi-cistronic sequence coding for the Cre recombinase and the fluorescent protein tdTomato into the Ly6g locus (designated as Catchup mice) led to specific expression of Cre in neutrophils, allowing both genetic manipulation and cell tracing to an extent that had never been reached before.
Indeed, breeding of these mice into a strain carrying the Cre-activatable tdTomato reporter under the CAG promoter into the ROSA26 locus, giving rise to the Catchup IVM-red strain, demonstrated specific conditional expression of the tdTomato in neutrophils 18, 19 . Here, we have used this mouse strain to generate mice having a conditional expression of the diphtheria toxin receptor (DTR) and evaluated them in neutrophil depletion experiments.
We recently demonstrated that neutrophils are the main contributors of disease progression among tumor infiltrating immune cells in the Kras G12D/WT ; p53 fl/fl inducible model of autochthonous lung cancer (KP mice) 20, 21 . In these publications, neutrophil tumor promoting activity was assessed through depletion experiments based on anti-Gr1 ab (clone RB6-8C5) as the anti-Ly6G (clone 1A8) failed to deplete these cells. In the present study, we investigated the limitations of these abs observed in different research centers, identified a new method to achieve specific and efficient neutrophil depletion, and further used this method based on ab combination to reveal the impact of neutrophils on lung tumor microenvironment and progression.
Results
The anti-Ly6G ab clone 1A8 does not deplete neutrophils in C57BL/6 mice In surveying the scientific literature over a one-year period we found forty-five publications using the key words "(Neutrophils and (depletion))" on PubMed, in which the authors reported efficient neutrophil depletion. One-third of these publications were using anti-Gr1 ab to remove neutrophils in vivo, whereas two-thirds used anti-Ly6G ab (figure 1a). To assess whether these abs indeed deplete neutrophils, we investigated their effects in 14 weeks old Catchup IVM-red (C57BL/6) mice whose neutrophils can be easily and specifically identified based on tdTomato expression. We found that anti-Gr1 ab treatment strongly reduced the proportion of tdTomato positive neutrophils; however, the percentage of neutrophils remained unchanged upon anti-Ly6G treatment (figure 1b). To address if mouse strain, origin (produced in our facility or not), housing conditions or age could affect anti-Ly6G depletion activity, we compared mice of three different strains, C57BL/6J, BALB/c and FVB/N imported from Charles River, and treated them at different age: 9-weeks old (housed for two weeks in our facility) and 24-weeks old (housed for 17 weeks). In these experiments, we identified circulating neutrophils using flow cytometry as CD11b + , CD45 + , Ly6C int cells. All strains presented a proportion of neutrophils of 7.6% ± 2.1 among immune cells at nine weeks of age and anti-Ly6G treatment (200µg) led to neutrophil depletion reaching 71%, 90% and 95% in C57BL6/J, BALB/c and FVB/N strains respectively, one day after ab injection. In 24-weeks old mice (housed in our animal facility for 17 weeks) all strains showed a higher proportion of circulating neutrophils (14.3% ± 3.8) when compared to the same strain at 9-weeks of age and housed in our facility over two weeks. Depletion with anti-Ly6G treatment and using the same protocol was ineffective in C57BL/6J mice (average neutrophil proportion was 187% of the controls) whereas it remained efficient in BALB/c (92.7%) and FVB/N (84.31%) mice (figure 1c). These observations raised the possibility that age and/or housing conditions contribute to the resistance of C57BL/6J mice to neutrophil depletion. To address this, we imported 18-weeks old C57BL/6J mice from Charles River and treated them with anti-Ly6G ab after two weeks of acclimation in our mouse facility. In these mice, the proportion of circulating neutrophils was similar or lower in controls to what we observed in nine-weeks old mice (4.6%± 1.2). Nevertheless, the injection of 200µg of anti-Ly6G ab failed to change the proportion of neutrophils among immune cells (figure 1d). Hence, these observations suggest that neutrophil proportions in the circulation depend on the housing conditions in all strains of mice and that the anti-Ly6G ab is largely ineffective at depleting neutrophils in C57BL/6J mice.
Confirming our observations, results from two other Institutions (MGH, USA; CRCL/CLB, France) showed that depletion using anti-Ly6G ab was not effective in C57BL/6J mice following different treatment modalities (figure S1a and b).
Considering the important number of publications reporting anti-Ly6G ab based depletion of neutrophils in C57BL/6 mice, we decided to investigate what could be the main differences between our practice and what we can find in the literature. In the majority of publications using anti-Gr1, the validation of neutrophil depletion was done based on CD11b/Ly6C staining or blood smears. On the other hand, from thirty articles published the same year and using anti-Ly6G ab, ten identified neutrophils based on Ly6G and CD11b expression and only five provided evidence of neutrophil depletion using blood smears or CD11b/Ly6C staining (figure 1e). This prompted us to test different gating strategies based on anti-Ly6G, antiCD11b and anti-Ly6C co-staining on blood cells from Catchup IVM-red mice treated one day before with 200µg of anti-Ly6G ab (clone 1A8) or control ab. We observed that Ly6C int /CD11b + cells correspond well to the neutrophil population as 80% and 81% of these cells were expressing the tdTomato in both control and anti-Ly6G treated conditions, respectively. Alternatively, gating on neutrophils based on their granularity (side scatter high) and CD11b also contained non-neutrophil cells as only 62% and 53% of the gated cells were tdTomato positive, respectively in control and Ly6G ab treated mice. Importantly, we failed to detect any cells in the Ly6G hi /CD11b + gate in mice treated with the anti-Ly6G ab, demonstrating that masking or internalization of the Ly6G antigen occurs when mice are treated with anti-Ly6G (figure 1f). We performed a titration of the anti-Gr1, anti-Ly6G and antiLy6C antibodies on blood samples from Catchup IVM-red mice treated with either anti-Ly6G, anti-Gr1 or control abs (200µg/mouse 24 hours before blood sampling). Strikingly, in both anti-Gr1 and anti-Ly6G treated animals, staining of neutrophils (identified as tdTomato positive cells) is impossible with the anti-Ly6G ab. The anti-Gr1 ab gives a weak signal, which could be used to identify neutrophils when mice are treated with anti-Ly6G, and anti-Ly6C staining is not impacted by any of the treatments (figure S1c). Hence, the strategy that is used to monitor neutrophil depletion in the majority of papers using the anti-Ly6G ab is likely to be misleading. Finally, supporting the fact that anti-Ly6G treatment is most probably not effective in C57BL/6J mice, we observed that, over twenty articles using anti-Ly6G in that strain, only one provides valid data to evaluate neutrophil depletion but in this case, authors failed, in these correct settings, to show any significant impact on neutrophils in 10 to 13-weeks old mice (figure 1g).
Celerity of neutrophil clearance is the limiting factor to achieve neutrophil depletion
We demonstrated that treatment of C57BL/6J mice with anti-Ly6G ab ineffectively reduces the number of circulating neutrophils but, according to the literature, it is also clear that treating mice with this ab has an effect on neutrophil biology. Hence, we hypothesized that anti-Ly6G treatment leads to a qualitative change of circulating neutrophils. We treated C57BL/6J mice with anti-Ly6G or anti-Gr1 ab, then compared the remaining neutrophils to the control condition using Giemsa staining on blood smears. This demonstrated that both antiLy6G and anti-Gr1 abs lead to the replacement, in the circulation, of mature neutrophils showing full nuclear segmentation by immature cells displaying band C shape or bisegmented nuclei (figure 2a). Hence, both anti-Ly6G and anti-Gr1 abs are able to increase neutrophil renewal but the anti-Ly6G ab is less efficient as it only leads to a qualitative modification of neutrophils and fails to achieve a quantitative decrease of the circulating cells.
These findings suggest that anti-Ly6G treatment inefficiently depletes neutrophils due to rapid mobilization of immature neutrophils from the BM to the periphery. The anti-Ly6G ab is a ratIgG2a isotype orthologous to the mouse IgG1 heavy chain, whereas the anti-Gr1 ab is a ratIgG2b isotype orthologous to the mouse IgG2a heavy chain 22 . We reasoned that this difference could explain why only the anti-Gr1 ab can decrease the number of circulating neutrophils. To investigate this, we combined the anti-Ly6G ab with a mouse IgG2a ab recognizing the rat IgGk light chain (clone MAR 18.5 that will bind to the anti-Ly6G ab). To do so, we sequentially treated 12 weeks old Catchup IVM-red mice with anti-Ly6G (n=9) or control ab (n=4) (day one) followed by anti-rat injection (day two) for every mouse except four of the ones that received anti-Ly6G only. Monitoring of tdTomato + cells at day 3 revealed a complete depletion of neutrophils in the combination treatment (Ly6G plus anti-rat) but not in controls or when anti-Ly6G was given alone. Furthermore, the Ly6G epitope was hidden by treatment in all conditions where the mice were injected with anti-Ly6G, confirming the binding of anti-Ly6G ab on circulating neutrophils in vivo (figure 2b). We then investigated if anti-Ly6G alone or in combination with anti-rat-IgGk exacerbates neutropoiesis. We found that Lineage -(Lin -), Sca-1 + cKit + hematopoietic stem cells (LSK cells) were increased in number and proportion upon both treatments (figure 2c). Similarly, the two treatment modalities also led to an increase of the proportion and the number of common monocyte/granulocyte precursors (GMP) identified as Lin -cKit + CD41 Low CD150 -CD16/32 hi (figure 2d and S2a). Accordingly, we noticed that mature neutrophils identified as s100A9 + Ly6C + CD62L + CXCR2 + cells totally disappeared from BMs of animals treated with either anti-Ly6G or the combination (figure S2b).
Altogether, our results demonstrate that, contrasting to anti-Gr1, the anti-Ly6G ab fails to reduce quantitatively circulating neutrophils in C57BL/6J mice but modifies them qualitatively by increasing neutrophil renewal in peripheral blood. This is probably because the anti-Ly6G ab is a rat-IgG2a isotype orthologous of mouse IgG1. Hence, to achieve a complete depletion of these cells using the anti-Ly6G ab it is mandatory to combine it with an anti-rat-IgGk mouse IgG2a secondary ab.
Combining anti-Ly6G plus anti-rat IgGk abs achieves specific neutrophil depletion
Already existing transgenic mice such as the LysM-Cre 14 and MRP8-Cre 16 Catchup DTR mice than in wild type C57BL/6J animals. From that we concluded that comparison of our different depleting strategies was relevant only in regard to their specific control and not across mouse strains. We observed that mice treated with anti-Ly6G plus anti-rat-IgGk abs showed efficient, specific and long-lasting neutrophil depletion (day two:
88.1%, day five: 94.1% and day nine: 85.1%). As expected, anti-Gr1 ab treatment was highly efficient in depleting neutrophils over the treatment duration (day two: 98.4% and day five:
98.2%), followed by a restoration of neutrophil number at day nine (149%), four days after treatment interruption. Consistent with the fact that anti-Gr1 ab also binds to Ly6C, we observed a depletion of monocytes (95.4% and 83.3%) and Ly6C + CD8 + T cells (60.8% and 76.3%) at days two and five. Four days after treatment interruption (day nine), like for neutrophils, the number of monocytes went back to normal levels whereas Ly6C + CD8 + T cells remained depleted at 75.9%, demonstrating the low renewal capacity of this lymphocyte subtype in comparison to neutrophils and monocytes. Surprisingly, neutrophil depletion in Catchup DTR mice treated with DT did not work. To confirm that neutrophils are resistant to DT, we purified these cells, validated HB-EGF/DTR expression (figure S3a) and treated them in vitro with low to extremely high doses of DT. Supporting our in vivo observations, we did not observe any impact of DT on cell viability (figure S3b). As an internal control validating our experimental settings, the number of circulating CD4 + T cells was not impacted significantly by any treatment (figure 3b). Hence, our results demonstrate the efficacy and specificity of the ab combination approach and also suggest that DT-based strategies do not always work to deplete neutrophils, supporting the need to improve ab-based depletion strategies.
To challenge our approach based on anti-Ly6G plus anti-rat-IgGk, we treated mice over a two-weeks period and observed that in this setting neutrophil depletion loses its efficacy over time (figure S3c). By analyzing Ly6G staining in mice receiving only the antiLy6G ab and the mice treated with the ab combination, we observed that the Ly6G epitope was accessible for anti-Ly6G staining only in escaper mice (mice where neutrophil proportion was above 30% of the control at the end of the experiment) from the combination group. In other words, neutrophils in escaper mice are not fully covered by the anti-Ly6G ab injected in vivo hence flow cytometry Ly6G staining works on these cells. This suggests that the anti-rat IgGk antibody can accumulate in the serum of mice and neutralize the anti-Ly6G ab injected to target neutrophils (figure S3d). Accordingly, a positive correlation between the number of neutrophils and the mean fluorescence intensity (MFI) on remaining neutrophils of the antiLy6G-FITC ab used for flow cytometry was only observed in mice treated with the combination (figure S3e). Thus, a regular monitoring of Ly6G coverage by anti-Ly6G ab during treatment is critical to adjust the relative concentrations of each ab in order to sustain the efficient depletion for a long time period (see supplementary method part a).
Alveolar and interstitial macrophages are modulated by tumor-infiltrated neutrophils in lung cancer
To functionally interrogate the relevance of our new approach to deplete neutrophils we tested it on KP mice bearing well-established lung tumors. Similarly to our previous observations where neutrophils were depleted using anti-Gr1 ab 20 
Discussion
This technical report evaluates current practices allowing neutrophil depletion and proposes an optimized protocol to achieve this goal in a large variety of mouse models. We analyzed the literature and performed experiments in three independent institutions, showing that neutrophil depletion using the anti-Ly6G ab (clone 1A8) is not a reliable method in C57BL/6J mice as even at high doses the anti-Ly6G might only be used in mice younger than 12 weeks of age where it leads to a partial depletion (70%). The reproducibility of our observations in mice from different origins strongly suggest that resistance to Ly6G abmediated neutrophil depletion is linked with mouse age even if the impact of the microbiota and chronic inflammation could also be important 27 . Understanding why anti-Ly6G treatment works in FVB/N and BALB/c but not in C57BL/6J mice remains an important question. Our observations might highlight differences in hematopoiesis and/or efficiency of the antibody dependent phagocytosis (ADCP) or cell cytotoxicity (ADCC) between mouse strains.
Similarly, the fact that old C57BL/6J mice are more resistant to anti-Ly6G treatment might be linked with age-related NK cell functional decay 28 that could be associated with reduced ADCP, but this phenomenon is usually observed in mice much older than 12 weeks of age.
By using Catchup IVM-red mice we further demonstrate that it is not possible to validate neutrophil depletion in anti-Ly6G treated mice using the same ab for flow cytometry. Other abs are commercially available, such as anti-Ly6C, anti-Ly6B or anti-S100A9 abs. As an alternative to ab treatment, we have also generated Catchup DTR mice but neutrophils were unfortunately not sensitive to DT. Two main hypotheses might explain neutrophil resistance to DT in this Ly6G driven DTR expression model: 1) DTR is not expressed enough at the neutrophil membrane, 2) knowing that most of the cytotoxic activity of DT being largely dependent on protein synthesis inhibition 29 , it is possible that early differentiated Ly6G + neutrophils do not require anymore protein synthesis to reach the periphery and to survive for 12 hours 30 . Nevertheless, the Catchup DTR model could be relevant as protein synthesis might be important for neutrophil function in tissues. Interestingly, these results are contrasting with data from MRP8 DTR mice where neutrophils, together with a monocyte sub-population, disappear from the circulation upon DT treatment. This might suggest that MRP8 is expressed earlier than Ly6G during neutrophil biogenesis, at a stage of differentiation where progenitors remain sensitive to DT.
Although anti-Ly6G fails to deplete neutrophils in C57BL/6 mice, we are not claiming that it has no impact on neutrophil function as it has helped to identify numerous processes where neutrophils play a central role. We report here that treating mice with neutrophil depleting agents leads to the mobilization of stem cells, progenitors and neutrophil pools in the BM. This observation is supported by the fact that neutrophil phagocytosis in the BM is a central mechanism regulating HSC niches through inhibition of CXCL12 production by reticular cells 11 . Furthermore, neutrophil homeostasis is sensed in the gut by CD169 + macrophages in a process governing the IL23/IL17/G-CSF axis, which is pivotal in the regulation of granulopoiesis in the BM 7, 10 . Altogether, these results suggest that in C57BL/6J mice neutrophil depletion is impaired by exacerbated neutropoiesis. On the other hand, treating these mice with anti-Gr1 ab leads to profound neutrophil depletion suggesting that the celerity of neutrophil clearance is the limiting parameter in anti-Ly6G treated mice. As the anti-Ly6G ab has been proposed to deplete neutrophils though a mechanism dependent on macrophages 31 , we were able to establish neutrophil clearance by combining anti-Ly6G with a secondary ab 32 . This approach is to date the most efficient and specific method to deplete these cells even when compared to genetically engineered mice allowing LysM, MRP8 or Ly6G-based conditional DTR expression, strategies which show lack of specificity (only 80% of the target cells are neutrophils) 14, 17 or absence of effect on the number of circulating cells (this study).
The most obvious impact of neutrophil depletion on the immune signature was an increase in both AM and IM proportions in the tumor mass associated with a strong reduction of Treg infiltration and amplification. IM showed a lower expression of tumor-promoting genes such as Mmp9 33 and immunomodulatory mediators (Arg1, Nos2). Hence, neutrophil infiltration might link some of the alterations reported on lung tumor patients' AMs 34-36 . Finally, treating KP mice with anti-Ly6G ab alone failed to demonstrate any effect on tumor growth and the immune signature. In our previous study 20 we demonstrated that depleting neutrophils with anti-Gr1 ab sensitizes tumors to anti-PD1 immunotherapy. Furthermore, a retrospective study suggested that lung cancer patients' survival was lower following immunotherapy if they had received an antibiotic treatment before 37 . Our work raises the hypothesis that neutrophil interference with macrophage function ultimately contributes to immunosuppressive T cell response with increased Treg amplification in lung tumors. This is an interesting perspective that will require in-depth analyses. A mechanism through which neutrophils could dampen macrophages' pro-inflammatory functions and potential anti-tumor activity might be directly linked to aged neutrophil phagocytosis by these cells, a phenomenon leading to suppression of pro-inflammatory responses by macrophages in multiple tissues 39 .
To conclude, our work illustrates critical limitations inherent to the use of anti-Ly6G ab for neutrophil depletion. While we urge the scientific community to systematically use and report appropriate methods to validate neutrophil depletion, for the last ten years, it is possible that some effects reported from anti-Ly6G treatment in C57BL/6 mice in various models are linked to aged neutrophils rather than total neutrophil biological activity. Our work proposes an alternative method for specific and efficient neutrophil depletion.
Online Methods

Mice importation and housing conditions
All mouse experiments from the Ecole Polytechnique Fédérale de Lausanne were performed with the permission of the Veterinary Authority of the Canton de Vaud, Switzerland (license number VD2391). Mouse experiments at Massachusetts General Hospital were performed according to approved IACUC guidelines. Wild type C57BL/6 mice were purchased from Jackson Laboratory. KP1.9 tumors were injected intravenously as previously described 40 . Animals were maintained in a specific pathogen free (SPF) animal facility AniCan platform.
Management of the KP mouse model of lung tumor
The tumors were initiated upon in vivo transduction of lung epithelial cells with a viral vector delivering Cre recombinase to activate oncogenic Kras G12D and delete p53. Twelve-tofourteen-week-old mice were instilled intratracheally with 1500 Cre-active lentiviral units.
Neutrophil depletion was performed on week 25 after tumor initiation. To measure tumor volume, mice were anaesthetized using isoflurane and maintained under anesthesia during the scanning procedure. Lungs were imaged with a µCT (Quantum FX, PerkinElmer) at a 50-µm voxel size, with retrospective respiratory gating. Individual tumor volumes were measured and calculated using the Analyze software (PerkinElmer). c-e, g) Ctr + anti-rat (n=8), Ly6G (n=7) or anti-Ly6G + anti-rat (n=17).
Flow cytometry and cell sorting
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